

2016 Annual General Meeting

June 21, 2017
Venlo, the Netherlands



Agenda



1

Opening

Prof. Dr. Manfred Karobath
Chairman of the Supervisory Board



2

Managing Board Report for the year ended December 31, 2016 (“Calendar Year 2016”)



2016 Annual General Meeting
June 21, 2017
Venlo, the Netherlands

Peer M. Schatz
Chief Executive Officer



Forward looking and intended use statements

Safe Harbor Statement: This presentation contains both historical and forward-looking statements. All statements other than statements of historical fact are, or may be deemed to be forward looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from our own expectations and projections. Some of the factors that could cause actual results to differ include, but are not limited, to the following: general industry conditions and competition; risks associated with managing growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, and the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including factors such as general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; technological advances of our competitors and related legal disputes; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitor products; market acceptance of QIAGEN's new products and the integration of acquired technologies and businesses. For further information, please refer to "Risk Factors" section of reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC). We undertake no obligation, and do not intend, to update these forward-looking statements as a result of new information or future events or developments unless and to the extent required by law.

Regulation G: QIAGEN reports adjusted results, as well as results on a constant exchange rate (CER) basis, and other non-U.S. GAAP figures (generally accepted accounting principles), to provide additional insight on performance. In this presentation, adjusted results include adjusted net sales, adjusted operating expenses, adjusted EBITDA, adjusted diluted EPS and free cash flow. Adjusted results are non-GAAP financial measures QIAGEN believes should be considered in addition to reported results prepared in accordance with GAAP, but should not be considered as a substitute. QIAGEN believes certain items should be excluded from adjusted results when they are outside of its ongoing core operations, vary significantly from period to period, or affect the comparability of results with its competitors and its own prior periods. Please see the Appendix provided in this presentation "Reconciliation of Non-GAAP to GAAP Measures" for reconciliations of historical non-GAAP measures to comparable GAAP measures and the definitions of terms used in the presentation. QIAGEN does not reconcile forward-looking non-GAAP financial measures to the corresponding GAAP measures due to the high variability and difficulty in making accurate forecasts and projections that are impacted by future decisions and actions. Accordingly, reconciliations of these forward-looking non-GAAP financial measures to the corresponding GAAP measures are not available without unreasonable effort. However, the actual amounts of these excluded items will have a significant impact on QIAGEN's GAAP results.

GeneReader NGS System: The QIAGEN GeneReader® NGS System is intended for Research Use Only. This product is not intended for the diagnosis, prevention or treatment of a disease. QIAGEN Clinical Insight® is an evidence-based decision support software intended as an aid in the interpretation of variants observed in genomic sequencing data. The software evaluates genomic variants in the context of published biomedical literature, professional association guidelines, publicly available databases and annotations, drug labels and clinical-trials. Based on this evaluation, the software proposes a classification and bibliographic references to aid in the interpretation of observed variants. The software is not intended as a primary diagnostic tool by physicians or to be used as a substitute for professional healthcare advice. Each laboratory is responsible for ensuring compliance with applicable international, national and local clinical laboratory regulations and other accreditation requirements.

WE ARE EXPERIENCING A NEW AGE OF

SCIENTIFIC BREAKTHROUGHS



● Dramatic scientific advances are enabling breakthroughs in molecular biology

Sample to Insight 1) Source: Cisco Systems, GenBank and Alliance Bernstein

BUT WE STILL HAVE TO SIGNIFICANTLY IMPROVE HOW
WE ADDRESS SOME OF

THE WORLD'S MOST PRESSING CHALLENGES

How can we
further improve
outcomes for
patients?

How can we
improve
public safety?

How can we
develop better
and safer drugs?

How can we
achieve scientific
breakthroughs
even faster?

● We are still at the beginning of gaining valuable insights from molecular data

TO ADDRESS THESE CHALLENGES CUSTOMERS WANT


MOLECULAR INSIGHTS



Faster



Better



More efficiently

● The opportunity: Address demands for differentiated molecular testing solutions


QIAGEN solutions empower molecular testing from Sample to Insight




Faster



Better



More efficiently



BIOLOGICAL
SAMPLE

Sample Technologies

Assay Technologies

Bioinformatics

Automation systems

SAMPLE TO INSIGHT SOLUTIONS



VALUABLE
MOLECULAR INSIGHTS

● We help customers gain insights to improve healthcare and advance science


QIAGEN at a glance

- Leader in molecular testing solutions
- True hybrid covering continuum from Life Sciences to Molecular Diagnostics
- Core capabilities
 - Consumables
 - Automation systems
 - Informatics


Facts and figures

- 2016 sales ~\$1.34 billion
- Customers >500,000
- Global reach >35 countries
- Employees ~4,700
- Listing NASDAQ / Frankfurt

2016 sales by customer class




2016 sales by product type and region



● World leader in molecular testing solutions that enable valuable insights



QIAGEN sales accelerating into new growth trajectory



● QIAGEN's progress accelerating as U.S. HPV headwinds fade away

(1) Excluding the restructuring charge, which was recorded in Q4 2016 to implement various efficiency initiatives, not excluded from adjusted results.

Note: QIAGEN announced a new adjustment policy as of January 1, 2014, to no longer adjust for share-based compensation and non-M&A related restructuring charges, but to continue adjusting for M&A-related expenses. Data shown applies the policy retrospectively to 2009-2013.

Sample to Insight


			Customers						
			Life Sciences			Molecular Diagnostics			
Examples:			Academia	Pharma	Applied Testing	Clinical Healthcare			
Automation	Sample Technologies	Blood	#1	●	●	●	●	●	●
		Liquid biopsy	#1	●	●		●	●	
		Tissue	#1	●	●		●		●
		Other	#1	●	●	●	●	●	●
	Assay Technologies	PCR	#3	●	●	●	●	●	●
		NGS	New	●	●	●	●	●	●
		QuantiFERON	#1		●			●	●
		Other		●	●	●	●		
	BioX	Software and biological content	#1	●	●	●	●	●	●
				Life sciences research	Pharma R&D	Human ID / Food / Vet	Oncology	Infectious diseases	Immune monitoring
Key applications									

● Current ● Future

● Multiple drivers with one focus: Sample to Insight in molecular testing solutions

Sample to Insight PCR – Polymerase Chain Reaction NGS – Next-generation sequencing Other – Includes Hybrid Capture and ModaPlex BioX – Bioinformatics

Sample to Insight solutions: Key highlight areas



● Differentiated portfolio setting new trajectory for growth and value creation



QuantiFERON-TB: Advancing the global fight against Tuberculosis

Total latent TB
annual addressable
market:

**~65 million
tests**

2016 key achievements

- U.S. FDA submission of 4th-generation QuantiFERON-TB test; approved in June 2017
- Winning major tenders worldwide – including South Korea, United Kingdom and Abu Dhabi
- Accelerating to 25% CER growth pace in 2016





NGS: Driving dissemination into clinical use

~80%

of all NGS runs
conducted on
samples processed
with QIAGEN

2016 key achievements

- GeneReader NGS System wins >10% share of new oncology NGS benchtop placements
- Expanding universal solutions for highest quality in liquid biopsy applications
- Setting new standards for performance and accuracy with Digital NGS technology





Personalized Healthcare: Pioneer in companion diagnostics

More than

20

master collaboration
agreements

2016 key achievements

- >20 master collaboration deals in place with leading pharma and biotech companies
- Expanding portfolio to support use of novel immuno-oncology (I-O) therapies
- Broadening companion diagnostics offering to use with GeneReader NGS System



QIASymphony: Driving molecular testing dissemination

2017 target:

>2,000

cumulative installed systems

2016 key achievements

- Surpassing 2016 target for >1,750 cumulative installed placements
- Implementing sample processing solution for use with GeneReader NGS System
- Introducing automation protocols for QIAGEN gold-standard liquid biopsy solutions

QIAGEN:

#1

in Sample Technologies

2016 key achievements


- Leveraging MO BIO technology for complex microbiome sample processing
- Expanding leadership in liquid biopsy
- Making single-cell research accessible to every lab with QIAscout automation solution




The total amount of
sequence data
doubles
every 7 months

2016 key achievements


- Acquisition of OmicSoft⁽¹⁾ adds scalable data management system for vast NGS data
- Launching microbiome profiling workflows
- Expanding list of international partnerships - e.g. Genomics England Project





2017 ambitions

- Sample to Insight portfolio capturing opportunities
- Outlook for improving performance
- Commitment to increasing returns and creating greater value



Green development

- LEDs saving 225,000 kWh/year – 72% less energy
- Reusing waste water saves 16 million liters/year in U.S.

Economic progress

- Recognized as one of Germany's "Top Employers"
- Ranked as No.1 brand in image by diagnostic labs

Corporate citizenship

- 1,000 hours of volunteer time in Maryland in 2016
- German partnership to support refugee integration



Diverse global workforce

- ~4,700 employees
- ~60 nationalities
- ~50% women

Family support

- Kindergarden to support Hilden employees since 2008
- ~200 children have so far attended Kindergarten

Employee development

- ~35,000 hours per year of employee training
- 76 employees in QIAGEN Executive MBA until 2018




About QIAGEN N.V.


- Organized under the laws of Netherlands
- Listed on NASDAQ (New York)
- Member of TecDAX Index (Frankfurt)

Endorsing relevant principles

- Application of Dutch governance standards
- NASDAQ – Corporate Governance Rules



Analyst ratings (As of June 2017)



2016 IR activities


- Private shareholder day: ~30 participants
- Institutional conferences: ~20 events
- 1x1 investor meetings: ~450 meetings
- Extel: Top 3 TecDAX ranking for 3 years





2016: QIAGEN shares (Frankfurt)


QIAGEN share price development – Frankfurt Stock Exchange (euros)





2016: QIAGEN shares (NASDAQ)

QIAGEN share price development – NASDAQ (U.S. dollars)





Jun-2016 to Jun-2017: QIAGEN share performance (Frankfurt)


QIAGEN share price performance since AGM June 21, 2016 vs. indices
(As of June 19, 2017, euros)





Jun-2016 to Jun-2017: QIAGEN share performance (NASDAQ)

QIAGEN share price performance since AGM June 21, 2016 vs. indices
(As of June 19, 2017, U.S. dollars)





2017 YTD: QIAGEN share performance (Frankfurt)


2017 YTD share price performance vs. indices (As of June 19, 2017, euros)





2017 YTD: QIAGEN share performance (NASDAQ)


2017 YTD share price performance vs. indices (As of June 19, 2017, U.S. dollars)





2007 – 2017: QIAGEN share performance (Frankfurt)


Share price performance vs. indices (As of June 19, 2017)





2007 – 2017: QIAGEN share performance (NASDAQ)


Share price performance vs. indices (As of June 19, 2017)





2007 – 2017: QIAGEN share performance (S&P 500)

Share price performance vs. indices (As of June 19, 2017)





Summary



Reaccelerating performance after transformation

Sustainable sales growth and leverage trajectory

Emerging as a stronger, focused, differentiated leader

Committed to higher returns and greater value creation



2016 Annual General Meeting

June 21, 2017

Venlo, the Netherlands

Roland Sackers

Chief Financial Officer



Forward looking and intended use statements

Safe Harbor Statement: This presentation contains both historical and forward-looking statements. All statements other than statements of historical fact are, or may be deemed to be forward looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from our own expectations and projections. Some of the factors that could cause actual results to differ include, but are not limited, to the following: general industry conditions and competition; risks associated with managing growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, and the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including factors such as general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; technological advances of our competitors and related legal disputes; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitor products; market acceptance of QIAGEN's new products and the integration of acquired technologies and businesses. For further information, please refer to "Risk Factors" section of reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC). We undertake no obligation, and do not intend, to update these forward-looking statements as a result of new information or future events or developments unless and to the extent required by law.

Regulation G: QIAGEN reports adjusted results, as well as results on a constant exchange rate (CER) basis, and other non-U.S. GAAP figures (generally accepted accounting principles), to provide additional insight on performance. In this presentation, adjusted results include adjusted net sales, adjusted operating expenses, adjusted EBITDA, adjusted diluted EPS and free cash flow. Adjusted results are non-GAAP financial measures QIAGEN believes should be considered in addition to reported results prepared in accordance with GAAP, but should not be considered as a substitute. QIAGEN believes certain items should be excluded from adjusted results when they are outside of its ongoing core operations, vary significantly from period to period, or affect the comparability of results with its competitors and its own prior periods. Please see the Appendix provided in this presentation "Reconciliation of Non-GAAP to GAAP Measures" for reconciliations of historical non-GAAP measures to comparable GAAP measures and the definitions of terms used in the presentation. QIAGEN does not reconcile forward-looking non-GAAP financial measures to the corresponding GAAP measures due to the high variability and difficulty in making accurate forecasts and projections that are impacted by future decisions and actions. Accordingly, reconciliations of these forward-looking non-GAAP financial measures to the corresponding GAAP measures are not available without unreasonable effort. However, the actual amounts of these excluded items will have a significant impact on QIAGEN's GAAP results.

GeneReader NGS System: The QIAGEN GeneReader® NGS System is intended for Research Use Only. This product is not intended for the diagnosis, prevention or treatment of a disease. QIAGEN Clinical Insight® is an evidence-based decision support software intended as an aid in the interpretation of variants observed in genomic sequencing data. The software evaluates genomic variants in the context of published biomedical literature, professional association guidelines, publicly available databases and annotations, drug labels and clinical-trials. Based on this evaluation, the software proposes a classification and bibliographic references to aid in the interpretation of observed variants. The software is not intended as a primary diagnostic tool by physicians or to be used as a substitute for professional healthcare advice. Each laboratory is responsible for ensuring compliance with applicable international, national and local clinical laboratory regulations and other accreditation requirements.



2016: Overview (U.S. GAAP adjusted)

1 Strong 2016 performance

- +6% CER net sales growth in line with 2016 target
- Free cash flow up 22% to \$267 million

2 Sample to Insight portfolio transformation building momentum

- About one-third of sales from growth drivers
- Improving efficiency while sustaining sales momentum

3 Increasing returns and creating greater value

- ~\$245 million synthetic share repurchase done in January, part of \$300 million in returns by end-2017

2016 Key results

In \$ millions (Except EPS)	FY 2016 ⁽¹⁾	FY 2015 ⁽¹⁾	Change \$ / (CER)
Net sales (CER)	1,338.0	1,281.0	+4% / (+6%)
Operating income	98.8	179.5	-45%
Adj. operating income	256.6	318.4	-19%
Adj. operating income excl. charge ⁽²⁾	324.8	318.4	2%
Diluted EPS	\$0.34	\$0.55	
Diluted adj. EPS (CER)	\$0.87 / (\$0.90)	\$1.06	
Diluted adj. EPS (CER) excl. charge ⁽²⁾	\$1.11 / (\$1.14)	\$1.06	

(1) In Q4 2016, QIAGEN changed to the "multiple attribution method" accounting principle for equity-based compensation. Some figures for 2015 and the first nine months of 2016 have been revised with no meaningful change. No impact on Q4 2016 results.


(2) A restructuring charge was recorded in Q4 2016 to implement various efficiency initiatives, not excluded from adjusted results.
CER – Constant exchange rates p.p. – Percentage points



2016: Net sales and EPS


2016 net sales development

(In \$ billions)



2016 adjusted diluted EPS⁽¹⁾ development

(In \$ per share)



(1) 2016 EPS amounts exclude the restructuring charge recorded in Q4 2016 to implement various efficiency initiatives
 CER – Constant exchange rates p.p. – Percentage point bn - Billion



2016: Net sales by customer classes

	FY 2016 net sales \$1,338.0 million		
	Sales (In \$ m)	% CER change	% of sales
Consumables and related revenues	\$1,166	+6%	87%
Instruments	\$172	+5%	13%
Molecular Diagnostics ⁽¹⁾	\$663	+7%	50%
<i>Of which: U.S. HPV test sales</i>	\$33	-29%	3%
<i>MDx excluding U.S. HPV test sales⁽¹⁾</i>	\$630	+10%	47%
Applied Testing	\$120	+7%	9%
Pharma	\$262	+7%	19%
Academia	\$293	+4%	22%



● Solid growth trends across Life Science and Molecular Diagnostic customers

(1) Companion diagnostic co-development revenues for FY 2016 (\$32 million, +6% CER)

Growth rates at CER (Constant exchange rates)

Sales and sales contributions at actual FX rates


Tables may contain rounding differences




2016: Geographic regions

FY 2016 net sales
\$1,338.0 million


	Sales (In \$ m)	% CER change	% of sales
Americas ⁽¹⁾	\$627	+5%	47%
Europe / Middle East / Africa	\$428	+8%	32%
Asia-Pacific / Japan	\$279	+11%	21%



Americas



Europe / Middle East / Africa



Asia-Pacific / Japan

● 2016 Top 7 emerging markets +19% CER and ~16% of total sales

(1) Americas excluding U.S. HPV FY 2016 (+8% CER)

Sales figures and sales contributions at actual FX rates

Growth rates at CER



2016: Key results

(In \$ millions, unless indicated) (Diluted EPS in \$ per share)	Full year		
	2016 ⁽¹⁾	2015 ⁽¹⁾	Change
Net sales	1,338.0	1,281.0	+4% (+6% CER)
<i>Gross profit margin</i>	63%	65%	
<i>Adjusted gross profit margin</i>	70%	71%	
Operating income	98.8	179.5	-45%
<i>Operating income margin</i>	7%	14%	
Adjusted operating income	256.6	318.4	-19%
<i>Adjusted operating income margin</i>	19%	25%	
Adjusted operating income excl. charge ⁽²⁾	324.8	318.4	2%
<i>Adjusted margin excl. charge⁽²⁾</i>	24%	25%	
Net income	80.4	130.1	
Adjusted net income	207.9	252.6	-18%
Tax rate	NM	5%	
Adjusted tax rate	12%	17%	
EPS (\$ per share) ⁽³⁾	0.34	0.55	
Adjusted EPS (CER) ⁽³⁾	0.87 (0.90)	1.06	
<i>Pre-tax restructuring charge⁽²⁾</i>	79.1		
Adjusted EPS excl. charge (CER) ⁽²⁾⁽³⁾	1.11 (1.14)		

CER – Constant exchange rates

NM – Not meaningful

Results for net income and EPS based on income attributable to owners of QIAGEN N.V.

(1) In Q4 2016, QIAGEN changed to the “multiple attribution method” accounting principle for equity-based compensation. Some figures for 2015 and the first nine months of 2016 have been revised with no meaningful change. No impact on Q4 2016 results.

(2) A restructuring charge was recorded in Q4 2016 to implement various efficiency initiatives, not excluded from adjusted results

(3) Weighted number of diluted shares (FY 2016: 239.0 million, FY 2015: 238.6 million)



2016: Reconciliation of reported to adjusted results (U.S. GAAP)

In \$ millions (Except EPS) (unaudited)	Net sales	Gross profit	Operating income	Pretax income	Income tax	Tax rate	Net income	Diluted EPS
Full-year 2016								
Reported results	1,338.0	844.7	98.8	56.9	23.4	NM	80.4	0.34
Adjustments								
Business integration and acquisition-related items		7.5	38.6	38.6	-11.4		27.2	0.11
Purchased intangibles amortization		80.1	119.2	119.2	-40.2		79.0	0.33
Non-cash interest expense charges				19.8			19.8	0.08
Other special income and expense				1.7	-0.2		1.5	0.01
Total adjustments		87.6	157.8	179.3	-51.8		127.5	0.53
Adjusted results	1,338.0	932.3	256.6	236.2	-28.4	12%	207.9	0.87
For information								
<i>Restructuring charge</i>		12.0	68.2	79.1	-22.1		57.0	0.24
Adjusted results excluding restructuring charge	1,338.0	944.3	324.8	315.3	-50.5	16%	264.9	1.11

Table may have rounding differences.

Net income and diluted EPS based on net income attributable to owners of QIAGEN N.V.

Adjusted diluted EPS in \$ per share using 239.0 million diluted shares.




2016: Review of U.S. GAAP and IFRS results

Consolidated Income Statements for the year ended December 31, 2016

Reconciliation of net income from IFRS to U.S. GAAP

(In \$ millions)



(1) Under U.S. GAAP Upper Call is recorded in equity at historical cost; under IFRS Upper Call is a liability subject to fair value remeasurement.

(2) IFRS tax results include deferred compensation costs for share-based compensation and higher intercompany eliminations than under U.S. GAAP.



2016: Review of U.S. GAAP and IFRS results

Consolidated Income Statements for the year ended December 31, 2016

In \$ millions (Except per share data)	U.S. GAAP 2016	IFRS 2016	Difference (U.S. GAAP vs. IFRS)
Net sales	1,338.0	1,338.0	
Gross profit	844.7	834.0	10.6
Income from operations	98.8	90.3	8.5
Net income	80.3	49.3	31.0
Earnings per share attributable to equity holders of QIAGEN N.V.			
Weighted average number of common shares, basic	234.8	234.8	
Basic in \$ per share	\$0.34	\$0.21	\$0.13
Weighted average number of common shares, diluted	239.0	239.0	
Diluted in \$ per share	\$0.34	\$0.21	\$0.13



2016: Balance sheet and cash flow


Balance sheet data

(As of December 31)	2016	2015
Group liquidity (In \$ millions)	532	421
Net debt (In \$ millions)	537	642
Shareholder equity ratio	61%	61%
Leverage ratio ⁽¹⁾	1.2x	1.6x

Cash flow

(In \$ millions)	2016	2015
Net cash provided by operating activities	342	318
Purchases of property, plant and equipment	-75	-98
Free cash flow	267	220


Leverage ratio⁽¹⁾



● Increasing returns with healthy balance sheet and improving free cash flow

(1) Leverage ratio is calculated on trailing four quarters as net debt / EBITDA adjusted for acquisition related expenses, equity-based compensation, pro forma results of acquired businesses and excluding 2016 restructuring charges.

Pro forma leverage ratio of 1.9x at December 31, 2016, including January 2017 payments for synthetic share repurchase and OmicSoft acquisition



Reinvest for organic growth

- Capture more value from our Sample to Insight portfolio
 - New products
 - Geographic expansion

Increase returns

- Commitment to return \$300 million by end of 2017
 - Completion of \$245 million synthetic share repurchase in January 2017

Targeted M&A / licensing


- Continuing our strategy
 - Novel technologies
 - Molecular test content
 - Geographic expansion

● Supporting our business expansion while increasing returns to shareholders



2016: Prudent financing structure offers strategic flexibility

Structure as of December 31, 2016



Convertible notes:


\$430 m 0.375% due 2019 (\$32.06 effective conversion price)
 \$300 m 0.875% due 2021 (\$32.06 effective conversion price)

U.S. Private Placement:

\$73 m 3.19% notes due 2019
 \$300 m 3.75% notes due 2022
 \$27 m 3.90% notes due 2024

Maturities of debt instruments

(In \$ millions)



Digitization: Increasing speed, relevance and impact of molecular insights

2020 sales goals

- 50% of sales via digital channels
- 50% customer accounts digitally integrated
- Increased automation and better forecasting



2020 efficiency goals

- >\$20 million cost efficiency improvement
- Central Digital Accelerator unit driving transformation
- Increased accuracy and speed in all processes

● Digitizing QIAGEN's business across the entire value chain



Employees as of December 31, 2016

	Americas	Europe / Middle East / Africa	Asia Pacific / Japan / ROW	Total 2016	Total 2015	Change
Production	261	622	113	996	1,000	0%
R&D	197	753	45	995	1,019	-2%
Sales	634	694	581	1,909	1,762	8%
Marketing	75	158	75	308	314	-2%
Admin	93	316	67	476	463	3%
Total	1,260	2,543	881	4,684	4,558	3%



Summary



2016: Solid performance as portfolio builds momentum

Growth drivers at forefront of QIAGEN transformation

Stronger, more differentiated molecular testing leader

Committed to higher returns and greater value creation



3

- a. Supervisory Board Report on the Company's Annual Accounts (the "Annual Accounts") for Calendar Year 2016
 - b. Report of the Compensation Committee of the Supervisory Board for Calendar Year 2016
-



4

Adoption of the Annual Accounts for Calendar Year 2016
(voting item)



5

Reservation and dividend policy



6

Discharge from liability of the Managing Directors for the performance of their duties during Calendar Year 2016 (voting item)



7

Discharge from liability of the Supervisory Directors for the performance of their duties during Calendar Year 2016 (voting item)



8

(Re-) Appointment of the following Supervisory Directors of the Company for a one-year term ending at the close of the Annual General Meeting in 2018 (voting item)

- a. Mr. Stéphane Bancel
- b. Dr. Håkan Björklund
- c. Dr. Metin Colpan
- d. Prof. Dr. Manfred Karobath
- e. Prof. Dr. Ross L. Levine
- f. Prof. Dr. Elaine Mardis
- g. Mr. Lawrence A. Rosen
- h. Ms. Elizabeth E. Tallett



Dr. Håkan Björklund

New member of Supervisory Board

- Operating Executive Avista Capital Partners
- Current Chairman at Swedish Orphan Biovitrum AB
- Previously Chairman of Lundbeck, also prior Board member at Alere, Coloplast, Atos Medical and Danisco
- Former CEO of Nycomed, senior leadership roles at Astra (now AstraZeneca) and Astra Draco
- Ph.D. in Neuroscience from Karolinska Institutet



Supervisory Board members

Supervisory Board members



Prof. Dr.
Manfred Karobath



Stéphane
Bancel



Dr. Håkan
Björklund



Dr. Metin
Colpan



Prof. Dr. Elaine
Mardis



Prof. Dr. Ross
Levine



Lawrence A.
Rosen






Elizabeth E.
Tallett

● Six new Board members appointed since 2011 with broad range of experience



Supervisory Board committees

	Independent	Audit Committee	Compensation Committee	Selection and Appointment Committee	Science and Technology Committee
 Prof. Dr. Manfred Karobath	✓		✓	✓ Chair	✓
 Stéphane Bancel	✓	✓	✓		✓
 Dr. Håkan Björklund.	✓		✓	✓	
 Dr. Metin Colpan	✓			✓	✓ Chair
 Prof. Dr. Elaine Mardis	✓				✓
 Prof. Dr. Ross Levine	✓				✓
 Lawrence A. Rosen	✓	✓ Chair			
 Elizabeth E. Tallett	✓	✓	✓ Chair	✓	



9

Reappointment of the following two Managing Directors of the Company for a term ending on the date of the Annual General Meeting in 2018 (voting item)

- a. Mr. Peer M. Schatz
 - b. Mr. Roland Sackers
-



10

Reappointment of KPMG Accountants N.V. as auditors of the Company for the calendar year ending December 31, 2017 (voting item)



11

Authorization of the Supervisory Board, until December 21, 2018 to:

- a. issue a number of Common Shares and financing preference shares and grant rights to subscribe for such shares, the aggregate par value of which shall be equal to the aggregate par value of all shares issued and outstanding in the capital of the Company as at December 31, 2016 as included in the Annual Accounts for Calendar Year 2016, (voting item); and
- b. restrict or exclude the pre-emptive rights with respect to issuing shares or granting subscription rights, the aggregate par value of such shares or subscription rights shall be up to a maximum of twenty percent (20%) of the aggregate par value of all shares issued and outstanding in the capital of the Company as at December 31, 2016 (voting item)



12

Authorization of the Managing Board, until December 21, 2018, to acquire shares in the Company's own share capital (voting item)



Agenda



13

Questions



Agenda



14

Closing





Thank you



Wir möchten Sie herzlich zu unserem QIAGEN Private Investor Day 2017

am 29. September, 2017
von ca. 11:00 – 16:00

bei QIAGEN in
Hilden, Deutschland einladen

Kontakt:

Alexandra König

+49 2103 29 11709

E-Mail: alexandra.koenig@qiagen.com

